Pipeline: nab-sirolimus

PopulationsPhase 1Phase 2RegistrationalApprovedCurrent Status
Advanced Malignant PEComa
AMPECT Clinical Trial

Single Agent

 
First FDA approved therapy for advanced malignant PEComa
precision-logoTumor-agnostic TSC1/TSC2 Inactivating Alterations

TSC1 Arm, Single Agent

 
Tumor-agnostic pivotal study with independent arms for TSC1 and TSC2 inactivating alterations; open for enrollment
Tumor-agnostic TSC1/TSC2 Inactivating Alterations

TSC2 Arm, Single Agent

 
Advanced solid tumors or NSCLC with KRASG12C mutation (Phase 1/2)

nab-sirolimus + adagrasib

 
Collaboration ongoing with
mirati-logo
DrugIndicationStage
Advanced Malignant PEComa
AMPECT Clinical Trial
First FDA approved therapy for advanced malignant PEComa
Single AgentCurrent Status
precision-logoTumor-agnostic TSC1/TSC2 Inactivating Alterations
Tumor-agnostic pivotal study with independent arms for TSC1 and TSC2 inactivating alterations; open for enrollment
TSC1 Arm, Single AgentApproved
Tumor-agnostic TSC1/TSC2 Inactivating Alterations
TSC2 Arm, Single AgentApproved
Advanced solid tumors or NSCLC with KRASG12C mutation (Phase 1/2)
Collaboration ongoing with
mirati-logo
nab-sirolimus + adagrasibPhase 2

Evaluation of additional new single agent and combination trials ongoing

Ongoing

To be initiated / In planning